Monopar Therapeutics MNPR Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $0— | $0— | $0— | —— | ||
| $9.9M-23.8% | $13.01M+132% | $5.6M-26.2% | $7.59M+16.9% | ||
| $6.8M+115% | $3.16M-2.3% | $3.23M+9.7% | $2.95M+11.8% | ||
| $16.7M+3.4% | $16.16M+83.0% | $8.83M-16.2% | $10.54M+15.4% | ||
| $16.7M+3.4% | $16.16M+83.0% | $8.83M-16.2% | $10.54M+15.4% | ||
| -$16.7M-3.4% | -$16.16M-83.0% | -$8.83M+16.2% | -$10.54M-15.4% | ||
| $2.99M+639% | $404.02K— | —— | —— | ||
| -$13.72M+12.0% | -$15.59M-85.5% | -$8.4M+20.1% | -$10.52M-15.5% | ||
| -$1.85+55.1% | -$4.12-150% | -$1.65-98.8% | -$0.83— | ||
| 28.5M+104% | 14M-56.4% | 32.1M— | —— | ||
| -$13.56M+12.7% | -$15.54M-84.4% | -$8.43M-4.7% | -$8.05M-14.7% | ||
| -$2.56K— | —— | -$17.27K-488% | -$2.94K-162% | ||
| $157.32K+224% | $48.49K+936% | -$5.8K-139% | $15.04K— | ||
| -$16.7M-3.4% | -$16.16M-83.0% | -$8.83M+16.2% | -$10.54M-15.4% | ||
| -$16.7M-3.4% | -$16.16M-83.0% | -$8.83M+16.2% | -$10.54M-15.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Monopar Therapeutics profitable?
- Monopar Therapeutics is not currently profitable: it reported a net loss of $15.0M over the trailing twelve months.
- Where does Monopar Therapeutics's income statement data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.